471 related articles for article (PubMed ID: 18480103)
1. Bacterial cyanogenesis occurs in the cystic fibrosis lung.
Sanderson K; Wescombe L; Kirov SM; Champion A; Reid DW
Eur Respir J; 2008 Aug; 32(2):329-33. PubMed ID: 18480103
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa, cyanide accumulation and lung function in CF and non-CF bronchiectasis patients.
Ryall B; Davies JC; Wilson R; Shoemark A; Williams HD
Eur Respir J; 2008 Sep; 32(3):740-7. PubMed ID: 18480102
[TBL] [Abstract][Full Text] [Related]
3. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis.
Reid DW; Carroll V; O'May C; Champion A; Kirov SM
Eur Respir J; 2007 Aug; 30(2):286-92. PubMed ID: 17504792
[TBL] [Abstract][Full Text] [Related]
4. Biosignificance of bacterial cyanogenesis in the CF lung.
Anderson RD; Roddam LF; Bettiol S; Sanderson K; Reid DW
J Cyst Fibros; 2010 May; 9(3):158-64. PubMed ID: 20156704
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas siderophores in the sputum of patients with cystic fibrosis.
Martin LW; Reid DW; Sharples KJ; Lamont IL
Biometals; 2011 Dec; 24(6):1059-67. PubMed ID: 21643731
[TBL] [Abstract][Full Text] [Related]
6. Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosis.
Stutz MD; Gangell CL; Berry LJ; Garratt LW; Sheil B; Sly PD;
Eur Respir J; 2011 Mar; 37(3):553-8. PubMed ID: 20562125
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
[TBL] [Abstract][Full Text] [Related]
8. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
Bradbury R; Champion A; Reid DW
Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N
Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571
[TBL] [Abstract][Full Text] [Related]
10. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G
APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034
[TBL] [Abstract][Full Text] [Related]
11. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
Hansen CR; Pressler T; Koch C; Høiby N
J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
[TBL] [Abstract][Full Text] [Related]
12. Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa.
Williams HD; Zlosnik JE; Ryall B
Adv Microb Physiol; 2007; 52():1-71. PubMed ID: 17027370
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
Reid DW; Latham R; Lamont IL; Camara M; Roddam LF
J Cyst Fibros; 2013 Dec; 12(6):688-99. PubMed ID: 23706827
[TBL] [Abstract][Full Text] [Related]
14. Clinical profile of adult cystic fibrosis patients with frequent epidemic clones of Pseudomonas aeruginosa.
Tingpej P; Elkins M; Rose B; Hu H; Moriarty C; Manos J; Barras B; Bye P; Harbour C
Respirology; 2010 Aug; 15(6):923-9. PubMed ID: 20573059
[TBL] [Abstract][Full Text] [Related]
15. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.
Sajjan US; Tran LT; Sole N; Rovaldi C; Akiyama A; Friden PM; Forstner JF; Rothstein DM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3437-44. PubMed ID: 11709321
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients.
Schelstraete P; Van Daele S; De Boeck K; Proesmans M; Lebecque P; Leclercq-Foucart J; Malfroot A; Vaneechoutte M; De Baets F
Eur Respir J; 2008 Apr; 31(4):822-9. PubMed ID: 18094014
[TBL] [Abstract][Full Text] [Related]
17. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.
Hansen CR; Pressler T; Nielsen KG; Jensen PØ; Bjarnsholt T; Høiby N
J Cyst Fibros; 2010 Jan; 9(1):51-8. PubMed ID: 19939747
[TBL] [Abstract][Full Text] [Related]
18. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
19. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.
Tunney MM; Field TR; Moriarty TF; Patrick S; Doering G; Muhlebach MS; Wolfgang MC; Boucher R; Gilpin DF; McDowell A; Elborn JS
Am J Respir Crit Care Med; 2008 May; 177(9):995-1001. PubMed ID: 18263800
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum.
Schiller NL; Millard RL
Pediatr Res; 1983 Sep; 17(9):747-52. PubMed ID: 6413945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
